
EPA Employees Still in the Dark as Agency Dismantles Scientific Research Office
Employees of the crucial scientific research arm of the Environmental Protection Agency (EPA) have been left with more questions than answers as the agency moves to officially wind down the office following months of back-and-forth.
On Friday evening, the EPA issued a press release announcing a reduction in force at the Office of Research and Development (ORD), citing the move as part of a larger effort to save a purported $748.8 million. On Monday, some employees at ORD, the largest office in the agency, began receiving emails detailing that they had been assigned new positions within the EPA.
'Please note, this is not an offer, but a notice of reassignment,' says a letter sent to an employee and viewed by WIRED states; the employee had previously applied to positions within the agency, as ORD employees were instructed to do in May. 'There is no action you need to take the reassignment, and there is no option to decline.'
On a call with ORD administrators and staff held Monday afternoon, audio of which was obtained by WIRED, leadership—including ORD acting administrator Maureen Gwinn—was unable to answer basic questions from employees, including a timeline for when the agency planned to permanently end ORD, how many employees would be transferred to other offices, and how many would lose their jobs. Employees at ORD who spoke with WIRED say that Friday's public-facing email was the first concrete news they had heard about their organization's future. One worker told WIRED that employees often learned more from news outlets, including WIRED, 'than we do from our management.'
"We wish we had more information for you," Gwinn told staff on the call. "I'll speak for myself, I wish we weren't at this point today."
An EPA spokesperson, who declined to give their name, wrote in response to a series of questions from WIRED that the agency is currently offering its third voluntary resignation period, known as a DRP, which ends on July 25. 'The RIF process entails a number of specific procedures in accordance with OPM regulations,' they said. 'The next step in this process is to issue intent to RIF notices to individual employees.' That number 'won't be clear,' they said, until after the DRP process was over.
'This is not an elimination of science and research,' the spokesperson wrote. 'We are confident EPA has the resources needed to accomplish the agency's core mission of protecting human health and the environment, fulfill all statutory obligations, and make the best-informed decisions based on the gold standard of science.'
At the start of the year, ORD was composed of between one and two thousand scientists at labs spread across the country as well as in Washington, DC. The branch's work provides much of the science that underpins the policy formed in the agency, from research on chemicals' impacts on human health and the environment to air quality and climate change to planning for emergencies and responding to contaminations in air, soil, and water. The office contains many groups and initiatives that are crucial to protecting the environment and human health, including a team that studies human health risks from chemicals.
Several EPA scientists stressed to WIRED that ORD's current structure, which allows research to happen independent of the policy-making that occurs in other parts of the agency, is crucial to producing quality work. One told WIRED that they worked in a scientific role in an EPA policy office under the first Trump administration. There, they felt that their job was to 'try and mine the science to support a policy decision that had already been made.' The structure at ORD, they said, provides a layer of insulation between decision-makers and the scientific process.
ORD was heavily singled out in Project 2025's Mandate for Leadership document, the policy blueprint that has closely anticipated the Trump administration's moves in office. It described the branch as 'precautionary, bloated, unaccountable, closed, outcome-driven, hostile to public and legislative input, and inclined to pursue political rather than purely scientific goals.' The plan did not, however, propose doing away with the organization. But in March, documents presented to the White House by agency leadership proposed dissolving ORD, resulting in backlash from Democrats in Congress.
In early May, the EPA announced it would be reorganizing its structure, which administrator Lee Zeldin wrote in a Newsweek op-ed would 'improve' the agency by 'integrating scientific staff directly into our program offices." The agency said that it would create a new Office of Applied Science and Environmental Solutions (OASES), which would sit under the Office of the Administrator.
Putting much of ORD's scientific work in policy offices, the scientist who previously worked in a policy office told WIRED, means that 'we're going to end up seeing science that has been unduly interested by policy interests. I don't think that's going to result in policy decisions that are empirically supportable.'
Following May's reorganization announcement, ORD employees were encouraged to apply for jobs within other parts of the agency. Multiple workers who spoke with WIRED say that the job postings for these new positions were barebones, with few descriptions of what the work would actually entail. One job posting seen by WIRED labels the posting simply as 'Interdisciplinary Scientific & Engineering Positions,' with no information about the topic area, team, or scientific expertise required.
The EPA's reorganization efforts were temporarily stalled by lawsuits. Earlier this month, the Supreme Court paused a preliminary injunction blocking further mass reductions in force at 17 federal agencies, including the EPA.
There was one bright spot on Monday's call: ORD leadership told employees that all of the ORD-affiliated labs would be kept open, a piece of news that ran contrary to some previous reports. Still, workers say that it's becoming increasingly difficult to do science at EPA. More than 325 ORD workers—around a fifth of ORD's ranks—had taken voluntary retirements since the start of the year, according to the EPA spokesperson. A scientist told WIRED that while they usually would have had a small team helping with their field work, they've been left to handle everything alone, including 'washing dishes and labeling bottles.' Cumbersome new financial approval processes, they said, have also resulted in chemicals that they ordered being delayed for months and expensive equipment sitting without any repairs.
Since taking office, Zeldin has made it clear that he intends to relax environmental regulations, especially around business: Last week, he authored an op-ed in Fox News advertising how the agency would essentially erase the Clean Air Act permitting process for power plants and data centers in order to 'make America the AI capital of the world.' ORD scientists fear that the dissolution of their office will only make this pro-business mission easier.
'If you're going to end up rolling back air quality regulations—and we know, conclusively at this point, that ozone pollution is causing premature mortality and chronic effects—if you roll back the rules, you're going to see excess cases of death and illness,' one scientist tells WIRED. 'My guess is that [EPA leadership] don't want to know the answer to the question of how bad it is going to be.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Analyst Says Advanced Micro Devices (AMD) Can Get $25 Billion in GPU Sales With Just 5% Market Share
Advanced Micro Devices Inc (NASDAQ:AMD) is one of the 10 Stocks to Buy and Sell in 2025: Top Analyst Calls. Ben Reitzes, Melius Research managing director, recently said in a program on CNBC that Nvidia getting the permission to start selling AI chips in China is also 'great' for Advanced Micro Devices Inc (NASDAQ:AMD). He believes AMD could benefit if it manages to get even 5% of the total market share amid a rise in inference. 'Our thesis on Advanced Micro Devices Inc (NASDAQ:AMD) is I mean how could they—Lisa Su is real. She's great. She's very compelling. Nothing against Jensen, but how do they not get like 5% share of the market? Not even 10. If they get 5% of the market in 2028, that's 25 billion in GPU sales. That's like 950, 10 bucks in earnings. So, our bet on Advanced Micro Devices Inc (NASDAQ:AMD) is they have a good product. It's really good for inferencing and people are going to give them a look. So, we're hearing, you know, like Meta's a little more interested in some of the new stuff. X, XAI, OpenAI really interested. So our thesis there now, China for them is it could be like add 20% plus to their AI revenue, but they don't have—they just have one, the old chip they were selling. We need to hear about more chips to get more confident, but it's great for Advanced Micro Devices Inc (NASDAQ:AMD). Don't get me wrong. It's great for AMD.' Photo by Vishnu Mohanan on Unsplash Advanced Micro Devices (NASDAQ:AMD) bulls believe the market should stop comparing the company's chips with Nvidia and focus on its data-center growth and its competitive edge over other players like Intel. Advanced Micro Devices (NASDAQ:AMD)'s strong growth in the data center segment is indeed impressive, driven by Instinct GPU shipments and strong sales of EPYC CPUs. Advanced Micro Devices (NASDAQ:AMD) will continue to benefit from organic growth catalysts in this segment despite the competition from Nvidia. According to Goldman Sachs Research, global data center demand could surge by 160% by 2030. In the U.S., data centers are projected to use 8% of total power by 2030, up from 3% in 2022. McKinsey estimates that adding the required U.S. capacity will need over $500 billion in infrastructure investment by the decade's end. Longriver Partners Fund stated the following regarding Advanced Micro Devices, Inc. (NASDAQ:AMD) in its second quarter 2025 investor letter:
Yahoo
23 minutes ago
- Yahoo
Where Will Robinhood Markets Stock Be in 5 Years?
Key Points Robinhood's assets under management (AUM) have grown a stunning 70% in the last 12 months. Management is focused on innovation, which could lead to new revenue streams for the company. 10 stocks we like better than Robinhood Markets › Five years from now, I believe Robinhood Markets (NASDAQ: HOOD) stock will be higher than it is today. Granted, that's a vague prediction, but it's also one I feel pretty confident in. After all, while trying to pinpoint future stock prices is often a useless exercise, identifying long-term trends is far easier. So, what are these long-term trends, and why do they give me such confidence that Robinhood stock will rise over the next five years? Let's dig in and explore them one by one. Robinhood's growth engine First off, to get a grasp of where Robinhood stock might be five years from now, it's important to understand its current state of affairs. The company operates an online brokerage offering customers the ability to trade stocks, options, futures, crypto, and other financial instruments. However, it does not generate most of its revenue through traditional commissions. Instead, the company creates revenue in two main ways: First, it routes customer orders to various market makers, which pay Robinhood. This process is called payment-for-order-flow (PFOF). Second, the company generates net-interest revenue from the cash held in its customers' brokerage accounts. Currently, Robinhood has over $221 billion in assets under management (AUM). Growth of its AUM will drive higher PFOF revenue and net-interest revenue. What's more, Robinhood's AUM is growing at an incredible rate. For example, over the last year, the company's total AUM has grown from $130 billion to $221 billion, an increase of 70%. Robinhood's management Thanks to its business model and its surging popularity, Robinhood is growing rapidly. But, in my opinion, it's the company's management that will propel its stock higher over the next five years. Robinhood is led by co-founder and CEO Vlad Tenev, a 38-year-old Bulgarian-American with a penchant for thinking big. He has announced several innovative endeavors at Robinhood: Artificial intelligence (AI): Integrating AI into investing with the launch of Cortex, Robinhood's AI system. Tokenization: This could provide access for those seeking to monetize (and trade) everything from art to mortgages to private equity shares. Prediction markets: Robinhood has already launched some prediction contracts, allowing users to place bets on real-world outcomes, ranging from politics to economic data. In short, Tanev isn't satisfied with simply running another online brokerage. He wants to push the boundaries of what is possible and expand into other areas adjacent to the traditional brokerage segment. Where will Robinhood stock be in five years? While no one can say for sure where Robinhood stock will be in 2030, I do think the stock will rise from its current level. As of this writing, Robinhood has a market capitalization of around $100 billion. That makes it around the 100th-largest company in America -- roughly the same size as Intel. By 2030, I think RobinHood could move up in that ranking, perhaps challenging one of its rivals, Charles Schwab, which has a market cap of around $175 billion, making it about the 50th-largest American company. In any event, I think Robinhood's robust growth and visionary leadership make it a stock to consider right now. Should you invest $1,000 in Robinhood Markets right now? Before you buy stock in Robinhood Markets, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Robinhood Markets wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Charles Schwab is an advertising partner of Motley Fool Money. Jake Lerch has the following options: long January 2026 $30 calls on Robinhood Markets. The Motley Fool has positions in and recommends Intel. The Motley Fool recommends Charles Schwab and recommends the following options: short August 2025 $24 calls on Intel and short September 2025 $92.50 calls on Charles Schwab. The Motley Fool has a disclosure policy. Where Will Robinhood Markets Stock Be in 5 Years? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data